Nutritional modifiers of aging brain function: use of uridine and other phosphatide precursors to increase formation of brain synapses

Richard J Wurtman, M Cansev, T Sakamoto, and IH Ulus

Brain phosphatide synthesis requires three circulating compounds: docosahexaenoic acid (DHA), uridine, and choline. Oral administration of these phosphatide precursors to experimental animals increases the levels of phosphatides and synaptic proteins in the brain and per brain cell as well as the numbers of dendritic spines on hippocampal neurons. Arachidonic acid fails to reproduce these effects of DHA. If similar increases occur in human brain, administration of these compounds to patients with diseases that cause loss of brain synapses, such as Alzheimer’s disease, could be beneficial.

INTRODUCTION

Presumably, all of the information that flows through and out of the brain is mediated by neurotransmitters, released into synapses and subsequently bound to postsynaptic receptors. Diseases of aging, such as Alzheimer’s disease, decrease the number of synapses and thereby impair cognition, ultimately compromising most brain functions.

No currently available treatment strategy has been shown to increase the number of synapses in brains of Alzheimer patients or, for that matter, of normal people. The agents now available for treating Alzheimer’s disease act by amplifying (acetylcholinesterase inhibitors) or modulating (glutamate antagonists) the actions of particular neurotransmitters. These drugs have only small and transient therapeutic effects and apparently do nothing to either slow synaptic loss or accelerate the production of new synapses that might compensate for this loss. The loss is generally thought to result from the locally toxic effects of an endogenous peptide, amyloid beta (Aβ), or its aggregates on synapses themselves or on their anatomic precursor, dendritic spines. An extensive and often frustrating search has been pursued for several decades to find a treatment that might block Aβ formation, aggregation, or toxic effects or perhaps remove the Aβ using a monoclonal antibody. No solid evidence yet has shown that doing so will slow the course of Alzheimer’s disease or reverse synaptic and cognitive deficits.

Since synapses are composed principally of a special type of membrane, “synaptic membrane”, comprised of lipids, principally phosphatides, and a specific set of proteins, a strategy for increasing their number would require agents that increased the formation of both their lipid and protein components. It would also require amplifying the genetic instructions that cause adult neurons to differentiate to form the structures – dendritic spines and terminal boutons – that come into contact and thereby generate synapses. New studies have shown that treating animals concurrently with three particular phosphatide precursors present in the blood and formed endogenously (uridine and choline) or derived from foods (choline and omega-3 fatty acids) can have both of these effects: It increases brain phosphatides, synaptic proteins, neurite outgrowth, and the formation of...
dendritic spines. This treatment also enhances cognition and the release of some brain neurotransmitters in the animals. Moreover, administration of the phosphatide precursors (along with additional supporting nutrients) to patients with mild Alzheimer’s disease significantly improved cognition in an initial large-scale (212 patients) clinical trial, discussed below.6

PHOSPHATIDE PRECURSORS AND SYNAPTOGENESIS

If animals are treated for several weeks with uridine, choline, and the omega-3 fatty acid docosahexaenoic acid (DHA), the quantities of membrane synthesized from these compounds increase significantly, both in whole brain and per brain cell. Moreover, the brains also exhibit parallel changes in levels of proteins known to be associated with pre- and post-synaptic membranes.7

The biochemical mechanisms that underlie these responses involve an unusual kinetic property of enzymes in the phosphatide-producing Kennedy cycle, i.e., poor affinities for the substrates they transform to intermediates in phosphatide synthesis. This property allows relatively small increases in available levels of uridine, for example, to accelerate the production of UTP and CTP; of DHA to increase brain levels of diacylglycerol molecules containing DHA; and of choline to increase brain phosphocholine. The brain is unusual among organs in the extent to which some of its most characteristic biochemical reactions are controlled by substrate levels, and thus in the extent to which a key enzyme is saturated with its physiological substrate (and not by the enzyme’s activity, per se.). Since the substrates involved are often nutrients, this dependence allows nutrient consumption to have important effects on brain composition and function. Thus, for example, the rates at which brain neurons synthesize and release the monoamine neurotransmitters serotonin,8–10 acetylcholine (ACh),11 histamine,12 and dopamine13 can all be increased by raising brain levels of the nutrients that are their circulating precursors, i.e., tryptophan, choline, histidine, and tyrosine, respectively. Similarly, giving animals the three normally circulating phosphatide precursors increases brain levels of their end product, phosphatidylcholine (PC), as well as levels of the other major membrane phosphatides, per brain cell. This sensitivity to substrate concentrations allows phosphatide levels, the quantity of synaptic membrane, and, ultimately, the number of synapses to be affected by nutrient intake.

Synapses consist of a presynaptic terminal originating on an axon; the synaptic cleft; and the postsynaptic membrane, usually on a dendrite or cell body. Presynaptic terminals synthesize the neuron’s neurotransmitter, and, generally, store it in and release it, upon depolarization, from synaptic vesicles. The locus of this release, the synaptic cleft, is a fluid-filled space between the two neurons. The neurotransmitter then either diffuses to the postsynaptic membrane or is inactivated, by enzymatic degradation (e.g., for ACh, by acetylcholinesterase) or by reuptake into its neuron of origin. The postsynaptic membrane contains receptors to which the neurotransmitter can bind, as well as additional protein molecules that transduce the functional consequences of the receptor’s activation (e.g., “scaffolding” molecules such as PSD-95 and enzymes such as adenylate cyclase). Pre- and postsynaptic membranes contain similar lipids – principally phospholipids and cholesterol – however, the membranes differ from each other and from membranes elsewhere in the brain by virtue of the high concentration of polyunsaturated omega-3 fatty acids in their phosphatides, as well as the specific proteins each contains, as described below.

The postsynaptic membranes on which glutamate, the most widely used brain neurotransmitter, acts often contain characteristic postsynaptic densities, each housing a large number of different proteins, which initiate the further transduction of biologic signals generated by the transmitter-receptor complex. This transduction is accomplished by the opening or closing of protein channels in the membranes, which allows specific ions that affect the cell’s voltage to pass into or out of the cell, or by activating membrane-bound enzymes coupled to G-proteins, which synthesize intracellular second messengers.

The formation of a new synapse among, for example, hippocampal neurons that use glutamate as their neurotransmitter is usually initiated by the coming together of a presynaptic element, the terminal bouton, and a postsynaptic dendritic spine, a process facilitated by the motility of postsynaptic dendritic spines.14 A variety of environmental factors apparently can increase the number of dendritic spines; for example, administration to mice of the hormone ghrelin, which also crosses the blood-brain barrier (BBB), enhances memory performance and promotes long-term potentiation. Targeted disruption of the gene for ghrelin decreases dendritic spine numbers and memory performance,15 thus affirming the importance of dendritic spines in hippocampal synaptic transmission. Dendritic spines are also known to be particularly vulnerable in Alzheimer’s disease.16 In transgenic mice that overproduce Ap, dendritic spines and synapses are diminished by local amyloid plaques,17 and cognition is thus impaired early in the course of the disease, prior to the overt loss of neurons.

It is not yet possible to quantify the effects on synaptic number of any but the most neurotoxic biochemical treatments. Thus, estimates of changes in synaptic number must, in general, be extrapolated from surrogate measurements, e.g., of numbers of dendritic spines, of...
concentrations of synaptic proteins, or of behaviors known to involve particular neurons. Of these surrogates, the number of dendritic spines is generally believed to provide the best correlations with the actual number of synapses, since as many as 90% of dendritic spines ultimately become synapses.14–23

Although most brain synapses are formed during prenatal or early postnatal development, each survives for only days to months and thus must be renewed periodically throughout the individual’s lifespan.24 This continuing necessity is probably of major importance in underlying the brain’s plasticity and the individual’s ability to learn, since it allows specific, perhaps newly formed synapses to be associated with newly learned material.19,25 Early in development, most synaptogenesis occurs independent of neuronal depolarization and neurotransmitter release.26–27 In adulthood, however, the rate at which new synapses form and the ways new synaptic connections become configured are largely governed by neuronal activity. This allows very active synapses to facilitate the formation of additional synapses.19 Synaptogenesis can also be enhanced by the activation of particular neuronal genes, for example those for transcription factors like CREB (the cAMP response element-binding protein), which enhances synaptic formation,28–30 and for MEF2, which limits the potentially excessive formation of new synapses.19,31 In new neurons formed from stem cells in adult mouse hippocampus and making their initial synaptic contacts, it can be shown32 that new synapses start to come into being when a dendritic spine from one neuron comes into contact with a presynaptic bouton of another. Hence, the rate of synaptogenesis is dependent on the numbers of dendritic spines that happen to be available, and treatments like the nutrient mixture described in this report, which increase the number of dendritic spines, can also thereby promote synaptogenesis.

EFFECTS OF URIDINE, CHOLINE, AND OMEGA-3 FATTY ACIDS ON SYNAPTIC MEMBRANE FORMATION AND SYNAPTONEUROSIS

All cells utilize uridine, choline, and DHA and other fatty acids to form PC and the other phosphatide subunits which, when aggregated, constitute the major components of their membranes. PC, the principal such subunit in brain, is synthesized from these precursors by the CDP-choline cycle or the Kennedy cycle32; it also provides the phosphocholine moiety needed to synthesize sphingomyelin (SM), the other major choline-containing brain phospholipid. The phosphatidylcholine (PC) is also synthesized via the Kennedy Cycle, utilizing ethanolamine instead of choline, while phosphatidylethanolamine (PE), the third major structural phosphatide, is produced by exchanging a serine molecule for the choline in PC or for the ethanolamine in PE.

The CDP-choline cycle involves three sequential enzymatic reactions. In the first, catalyzed by choline kinase, a monophosphosphate is transferred from ATP to the hydroxyl oxygen of the choline, yielding phosphocholine. In the second, catalyzed by CTP : phosphocholine cytidylyltransferase (CT), cytidine-5’-monophosphate (CMP) is transferred from CTP to the phosphorus of phosphocholine, yielding cytidine-5’-diphosphocholine (also known as CDP-choline or citicoline). As discussed below, much of the CTP the human brain uses for this reaction derives from circulating uridine.33 In the third and last reaction, catalyzed by CDP-choline:1,2-diacylglycerol cholinephosphotransferase (CPT), the phosphocholine of CDP-choline is bonded to the hydroxyl group on the 3-carbon of diacylglycerol (DAG), yielding the PC. DAG molecules containing a polyunsaturated fatty acid (PUFA) at the 2-position are preferentially utilized for this reaction.44 All three PC precursors must be obtained by brain entirely or in large part from the circulation, and because the PC-synthesizing enzymes that act on all three have low affinities for these substrates, blood levels of all three can affect the overall rate of PC synthesis.35–37

Thus, choline administration increases brain phosphocholine levels in rats90 and humans,89 because choline kinase’s Km value for choline (2.6 mM)47 is much higher than usual brain choline levels (30–60 μM).38–40 Most commonly, the second CTP-catalyzed reaction most influences the overall rate of PC synthesis, either because not all of the CT enzyme is fully activated by being attached to a cellular membrane44 or because local CTP concentrations are insufficient to saturate the CT. Thus, when brain CTP levels are increased by giving animals uridine,42 CTP’s circulating precursor in human blood, and, also, by gavage, DHA, brain PC synthesis is accelerated.41 The activity of CPT and the extent to which this enzyme is saturated with DAG can also control the overall rate of PC synthesis21: In PC-12 cells, nerve growth factor increased DAG levels fivefold, CPT activity by 70%, and the incorporation of choline into PC twofold. If rodents are given a standard diet supplemented with choline and uridine (as its monophosphate, UMP) and, also, by gavage, DHA, brain PC synthesis rapidly increases74,72 and absolute levels of PC per cell (i.e., deoxyribonucleic acid [DNA]) or per milligram of protein rise substantially (e.g., by 30% or more after several weeks of daily treatment7 (Table 1).

This treatment also increases the levels of each of the other principal membrane phosphatides (Table 1), as well as those of particular proteins known to be localized within presynaptic and postsynaptic membranes (for example, synapsin-1, PSD-95, and syntaxin-3)44 (Table 2), but not of β-tubulin, a ubiquitously distributed protein.7,45
These changes in synaptic proteins are probably mediated by an additional mechanism66 discussed below: the activation of P2Y receptors by uridine or uridine-containing nucleotides. Administration of DHA, UMP, and choline to adult gerbils also promotes the formation of hippocampal dendritic spines,47 improves hippocampus-dependent cognitive behaviors in rats48,49 and gerbils,1 and can amplify neurotransmitter release.50,51 Providing supplemental UMP or DHA without the other can also increase brain phosphatide levels, although to a lesser extent than when all three precursors (including choline, which is present in all of the test diets) are given.

Sources of plasma and brain uridine

Few data are available as to whether foods other than milk contain significant quantities of free uridine or uridine-containing nucleotides, or whether consumption of any naturally occurring food, by adults, can substantially increase plasma uridine levels. What is known is that pyrimidines as well as purines are constituents of nucleic acids, i.e., ribonucleic acid (RNA), which contains uridine and cytidine, and DNA, which contains cytidine. Since RNA and DNA are components of all cells, any food consumed by humans that contains cells (e.g., meats, poultry, fish, vegetables, fruits, etc.) is, at least theoretically, a good source of nucleic acids and perhaps also of plasma pyrimidines. Evidence from in vitro studies suggests that, following enzymatic breakdown of dietary nucleic acids, pyrimidine compounds are taken up into the blood from the intestine, although no in vivo study has demonstrated, in adults, an actual increase in plasma uridine levels after eating an RNA- or DNA-containing food. The nucleic acids in foods or in breast milk have been shown in in vitro studies to be degraded to yield purine and pyrimidine nucleotides; nucleosides; and free bases.62,63 In vitro, RNA is digested by ribonucleases to yield uridine nucleotides, and these can be further hydrolyzed to uridine by phosphatases in the intestinal mucosa.64

Uridine is present as such in breast milk and also as constituents of RNA, nucleotides (5′-UMP), and nucleotide adducts (uridine-5′-diphosphate [UDP]-glucose, UDP-galactose).65,66 The total available uridine contents of pooled milk samples from 100 European women determined by a method that simulated in vivo digestion65 (i.e., by enzymatically degrading nucleic acids, nucleotides, and nucleotide adducts) were 32, 48, and 47 μM, respectively, for mothers of 2- to 10-day-old, 1-month-old, and 3-month-old babies. Available cytidine contents in the same samples were 86, 102, and 96 μM.65 Synthetic infant

### Table 1 Effects of UMP and DHA on brain phospholipid levels.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>PC</th>
<th>PE</th>
<th>SM</th>
<th>PS</th>
<th>PI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control diet + vehicle</td>
<td>152 ± 6</td>
<td>65 ± 4</td>
<td>45 ± 2</td>
<td>33 ± 3</td>
<td>2 ± 2</td>
</tr>
<tr>
<td>UMP diet + vehicle</td>
<td>171 ± 8*</td>
<td>84 ± 8*</td>
<td>52 ± 5</td>
<td>35 ± 3</td>
<td>31 ± 2**</td>
</tr>
<tr>
<td>Control diet + DHA</td>
<td>185 ± 12*</td>
<td>78 ± 5*</td>
<td>56 ± 3*</td>
<td>39 ± 3</td>
<td>32 ± 2**</td>
</tr>
<tr>
<td>UMP diet + DHA</td>
<td>220 ± 12***</td>
<td>113 ± 6***</td>
<td>73 ± 4***</td>
<td>46 ± 6***</td>
<td>36 ± 3***</td>
</tr>
</tbody>
</table>

* P < 0.05; ** P < 0.01; *** P < 0.001 when compared with the values for control diet + vehicle group. Gerbils consumed a control or a UMP-containing (0.5%) diet and received orally (by gavage) DHA (300 mg/kg) or its vehicle for 28 days. On day 29, their brains were harvested and assayed for phospholipids. Data are given as means ± SEM. Statistical analysis was performed using one-way ANOVA followed by the Tukey test.

**Abbreviations:** PC, phosphatidylcholine; PE, phosphatidylethanolamine; SM, sphingomyelin; PS, phosphatidylserine; PI, phosphatidylinositol.

Adapted from Wurtman et al. (2006).7

### Table 2 Effects of UMP and DHA on synaptic protein levels.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>PSD-95</th>
<th>Syntaxin-3</th>
<th>β-Tubulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control diet + vehicle</td>
<td>100 ± 11</td>
<td>100 ± 6</td>
<td>100 ± 1</td>
</tr>
<tr>
<td>UMP diet + vehicle</td>
<td>116 ± 8</td>
<td>116 ± 6</td>
<td>100 ± 1</td>
</tr>
<tr>
<td>Control diet + DHA</td>
<td>125 ± 11*</td>
<td>120 ± 10**</td>
<td>93 ± 2</td>
</tr>
<tr>
<td>UMP diet + DHA</td>
<td>142 ± 5***</td>
<td>131 ± 8***</td>
<td>102 ± 1</td>
</tr>
</tbody>
</table>

* P < 0.05; ** P < 0.01; *** P < 0.001 when compared with the values for control diet + vehicle group. Gerbils consumed a control or a UMP-containing (0.5%) diet and received orally (by gavage) DHA (300 mg/kg) or its vehicle for 28 days. On day 29, their brains were harvested and assayed for synaptic proteins using Western blots. In rodents receiving the control diet + vehicle (i.e., the control group), arbitrary values obtained from protein band intensities were normalized to 100 in order to compare data obtained from treatment groups as percentages of those of the control group. Statistical analysis was performed using one-way ANOVA followed by the Tukey test.

Adapted from Pooler et al. (2005).66

Nutrition Reviews® Vol. 68(Suppl. 2):••–••
formulas are also routinely fortified with uridine and cytidine monophosphates.

Uridine is transported across the intestinal mucosal epithelium as such\(^{57,58}\) or as uracil, the free base. In rat small intestine, cytidine derived from RNA or DNA is partly deaminated to uridine.\(^{52}\) In humans, this deamination in intestinal mucosa and liver is probably much greater than in rats, since exogenously administered cytidine is almost undetectable as such in human plasma.\(^{33}\)

The transport of pyrimidine nucleosides and bases across the small intestine is mediated by the sodium-dependent concentrative nucleoside transporters CNT1 and CNT2.\(^{39}\) The kinetic properties of this uptake have not yet been determined. Following intestinal absorption, uridine and uracil are transferred via the portal vein to the liver. In rats, the liver is probably the major organ modulating plasma uridine concentrations: more than 90% of the uridine that enters the liver via the portal vein is metabolized in a single pass\(^{30}\); moreover, uridine’s concentration in hepatic venous plasma (1.32 ± 0.45 μM) is slightly higher than in portal (1.03 ± 0.3 μM) or arterial (1.06 ± 0.2 μM) blood, indicating that some of the uridine in the hepatic venous blood derived from de novo hepatic synthesis.

Uridine and cytidine are transported across cellular membranes in all tissues,\(^{41}\) including the brain, via two families of transport proteins: the Na\(^+\)-independent, low-affinity, equilibrative transporters (ENT1 and ENT2; SLC29 family) and the Na\(^+\)-dependent, high-affinity, concentrative transporters (CNT1, CNT2, and CNT3; SLC28 family). The two ENT proteins exhibit Km values for both uridine and cytidine in the high micromolar range (100–800 μM)\(^{65}\); thus, they probably mediate BBB pyrimidine uptake only when plasma levels have been elevated experimentally. In contrast, CNT2, which transports both uridine and purines like adenosine, probably mediates BBB uridine transport under physiological conditions: its Km values for uridine (and adenosine) are in the low micromolar range (9–40 μM), whereas plasma uridine levels are subsaturating, i.e., 0.9–3.9 μM in rats, 3.1–4.9 μM in humans, and around 6.5 μM in gerbils. Pyrimidines also may be taken up into brain via the choroid plexus epithelium; however, because the surface area of the BBB is so much greater (i.e., in humans 21.6 m\(^2\) versus 0.021 m\(^2\)), it is clear the BBB is the major locus of uridine uptake.

Uridine and cytidine are phosphorylated to their respective nucleotides by various kinases. Thus, uridine-cytidine kinase (ATP : uridine 5’-phosphotransferase, Enzyme Commission [EC] no. 2.7.1.48) converts to UMP\(^{60,64}\); UMP is then converted to UDP by UMP-CMP kinase (ATP : CMP phosphotransferase, EC 2.7.4.14)\(^{65,67}\) and to UTP by nucleoside diphosphate kinases (nucleoside triphosphate: nucleoside diphosphate phosphotransferase, EC 2.7.4.6).\(^{64}\) Interconversions of uridine and cytidine and of their respective nucleotides also occur in mammalian cells. Cytidine and CMP can be deaminated to uridine and UMP\(^{68,69}\) while UTP is aminated to CTP by CTP synthase (UTP : ammonia ligase [ADP-forming], E.C. 6.3.4.2).\(^{69}\)

All of the above enzymes are unsaturated with their respective nucleoside or nucleotide substrates in brain and other tissues. For example, the Km values for uridine of uridine-cytidine kinase prepared from various tissues varied between 33 and 270 μM\(^{51,63,64}\) and prepared from recombinant mouse brain enzyme was 40 μM.\(^{70}\) Brain uridine and cytidine levels are about 22–46 pmol/mg wet weight\(^{65,71}\) and 6–43 pmol/mg wet weight,\(^{72}\) respectively. Hence, the syntheses of UTP and CTP, and the subsequent syntheses of brain PC and PE via the Kennedy pathway, depend on the availability of their pyrimidine substrates. Indeed, an increase in the supply of uridine or cytidine to neuronal cells, in vitro\(^{46,72,73}\) or in vivo,\(^{42}\) enhanced the phosphorylation of uridine and cytidine, elevating the levels of UTP, CTP, and CDP-choline.

Brain levels of particular uridine-containing compounds following uridine administration were examined in gerbils given a single dose of UMP (1 mmol/kg)\(^{42}\) by gavage and killed between 5 minutes and 8 hours thereafter. Thirty minutes after gavage, plasma uridine levels were increased from 6.6 ± 0.58 to 32.7 ± 1.85 μM (P < 0.001) and brain uridine levels from 22.6 ± 2.9 to 89.1 ± 8.82 pmol/mg tissue (P < 0.001). UMP also significantly increased plasma and brain cytidine levels. However, both basally and following UMP administration, these levels were much lower than those of uridine, rising from 1.2 μM to 1.9 μM in plasma and from 5 pmol/mg tissue to 12 pmol/mg tissue in brain 30–60 minutes after gavage. (In human subjects receiving oral cytidine as CDP-choline, plasma cytidine levels did not rise detectably at all).\(^{35}\) Brain UTP, CTP, and CDP-choline were all elevated in gerbils 15 minutes after UMP administration (from 254 ± 31.9 to 417 ± 50.2 [P < 0.05]; 56.8 ± 1.8 to 71.7 ± 1.8 [P < 0.001]; and 11.3 ± 0.5 to 16.4 ± 1 [P < 0.001] pmol/mg tissue, respectively), returning to basal levels after 20 and 50 minutes. The smallest UMP dose that significantly increased brain CDP-choline was 0.5 mmol/kg. These results show that oral UMP, a uridine source, enhances the synthesis of CDP-choline, the immediate precursor of PC, in gerbil brain, but the increases in nucleotides or CDP-choline are short-lived and disappear long before increases in brain phosphatidies become detectable. How, then, does repeated daily intake of supplemental uridine (as UMP in the test diet) ultimately raise brain PC? Probably, in part, via uridine’s other mechanism of action, discussed below: activation of P2Y receptors, which then elicit longer-term downstream effects.
Sources of plasma and brain choline

Choline is present in plasma as the free base, as a constituent of phospholipids (including PC, SM, lyso-PC, choline-containing plasmalogens, and platelet-activating factor), and as PC’s water-soluble metabolites (principally phosphocholine and glycerophosphocholine). Free choline is also found in other biologic fluids and concentrated within erythrocytes through the action of an uptake molecule that is unsaturated (Km value, 5–10 μM at normal plasma choline concentrations).

Plasma choline derives from three main sources: dietary choline, consumed as the free base or as a constituent of phospholipids; endogenous synthesis, principally in liver; and liberation from the membrane phosphatides of all mammalian cells. Choline is present within many foods (see http://www.nal.usda.gov/fnic/foodcomp/Data/Choline/Choline.html) and also in breast milk and infant formulas, principally as the free molecule or as phosphatides, and its plasma levels can rapidly increase several-fold after ingestion of choline-rich foods. Thus, consumption by humans of a five-egg omelet (containing about 1.3 g of choline) increased these levels from 9.8 μM to 36.6 μM within 4 hours. Prolonged fasting reduced human plasma choline levels from 9.5 μM to 7.8 μM after 7 days. Similarly, removal of all choline-containing foods from the diet for 17–19 days gradually lowered plasma choline, from 10.6 μM to 8.4 μM in humans and from 12.1 μM to 6.3 μM in rats, indicating plasma choline can be partially but not fully sustained by release from endogenous stores.

Dietary PC is decylated within the gut to form lyso-PC. About half of this product is further degraded to free choline within the gut or liver. The remainder is recy- lated to regenerate PC, which is then absorbed into the lymphatic circulation. Much of the dietary choline that reaches the liver via the portal circulation is destroyed by oxidation to betaine, ultimately providing methyl groups that can be used to regenerate S-adenosylmethionine (SAM) from homocysteine. The rest passes into the systemic circulation.

In 1998, the Food and Nutrition Board of the U.S. Institute of Medicine established a dietary reference intake (DRI) for choline. Since the Food and Nutrition Board did not believe existing scientific evidence allowed calculation of a Recommended Daily Allowance (RDA) for choline, it instead set an Adequate (daily) Intake (AI) level and an Upper (daily) Limit (UL) that should not be exceeded. The main criteria for determining the AI and UL were, respectively, the amount of choline needed to prevent liver damage, and the choline intake associated with choline’s most sensitive adverse effect, i.e., hypotension. It should be noted that subsequent studies have shown the enzymes, described below, that synthesize and metabolize choline can be affected by common genetic polymorphisms that cause important person-to-person variations in dietary choline needs. Further details about dietary reference intakes and the choline content of various foods are available on the official websites of the Institute of Medicine (http://www.nal.usda.gov/fnic/foodcomp/Data/Choline/Choline.html).

Endogenous choline is synthesized, principally in liver but also to a small extent within brain, by the sequential addition of three methyl groups to the amine nitrogen of PE; this forms PC, which can then be hydrolyzed to liberate the choline. The methylation reactions are catalyzed by two phosphatidylethanolamine-N-methyltransferase (PEMT) enzymes: PEMT1 (EC: 2.1.1.17), which converts PE to its monomethyl derivative, and phosphatidyl-N-methyltransferase (PEMT2; EC: 2.1.1.71), which adds the second and third methyl groups (a single enzyme may catalyze all three methylations in liver). Both enzymes utilize SAM as the methyl donor; their Km values for SAM are 2–4 × 10−6 M and 20–110 × 10−6 M, respectively, while brain SAM concentrations are 10–17 μg/g wet weight (50–85 μM, assuming about 50% of the brain mass is aqueous). Hence, PEMT1 is probably fully saturated with SAM, while PEMT2 is not. PEMT activity has been identified in brain homogenates, particularly in synaptosomes, suggesting nerve terminals can synthesize choline. PE itself is formed in liver, kidney, or brain from free ethanolamine via the CDP-ethanolamine cycle (Kennedy cycle) or from the decarboxylation of PS. PS is produced, in nerve terminals and elsewhere, by “base exchange,” in which a serine molecule substitutes for the ethanolamine in PE or for the choline in PC.

The biosynthesis of PC, and thus of endogenous choline, by the methylation of hepatic PE is diminished in animals given inadequate amounts of vitamins required for methyl group production, i.e., B6, B12, and folate. This relationship provides a basis for administering supplemental quantities of these vitamins to subjects receiving uridine, DHA, and choline to promote membrane phosphatide formation.

Free choline is liberated from PC by the phospholipase enzymes. Phospholipase D directly cleaves the choline/phosphate bond to generate choline and phosphatidic acid. Phospholipase A2 acts on the bond connecting a fatty acid to the hydroxyl group on PC’s number-2 carbon to yield that fatty acid (often arachidonic acid [AA] or DHA) and lyso-PC; the lyso-PC is then further metabolized to choline by a phosphodiesterase, or to glycerophosphocholine, then cleaved to choline by a phosphatase. Phospholipase C acts on the bond connecting the phosphate and the hydroxyl group...
on PC’s number-3 carbon to yield DAG and phosphocho-
line; the phosphocholine can then be metabolized to free
choline by a phosphatase.

It is estimated, on average, about 15% of the free
choline that enters the human bloodstream derives from
endogenous synthesis, the rest coming principally from
dietary sources. Acute or chronic liver disease or defi-
ciencies in methionine, folic acid, or vitamin B₁₂ intake
can thus lower plasma choline levels by impairing hepatic
PC synthesis.

Cellular membranes contain most of the choline in
the body, principally as PC and SM. They also contain, of
course, the phosphatidylcholine (PC), phosphatidylethanol-
amine (PE), and phosphatidylinositol (PI) as well as specific proteins, cholesterol, and various
minor lipids. The quantities of choline present in brain as
PC (2–2.5 mmol/g) or SM (0.25 mmol/g) are orders of
magnitude greater than those of free choline (30–60 μM).

PC is highly heterogeneous, actually representing a
family of compounds with differing fatty acid composi-
tions and, consequently, differing chemical and physical
properties. The fatty acid in the C-1 position of PC tends
most often to be saturated (e.g., stearic or palmitic acid),
while that in position C-2 is more likely to be monoun-
saturated (oleic acid) or polyunsaturated (e.g., the
omega-3 fatty acids DHA [22:6 n-3] and eicosapentaenoic
acid [EPA] [20:5 n-3] or the omega-6 fatty acid AA [20:4 n-6]).

Newly synthesized phosphatidylcholine molecules contain relatively
larger quantities of PUFA:s than the phosphatidyl-
choline molecules present at steady state. This reflects either
faster turnover of PUFAs-containing phosphatidylcholines, or
their rapid decylation followed by reacylation with
more-saturated fatty acid species, or both. Membranes of
retinal and brain cells are especially rich in PUFA:s, par-
ticularly DHA (which comprises about 20% of the total
fatty acids in retinal phospholipids and about 7% of those in brain phospholipids, respectively). As described
below, administration of supplemental DHA accelerates
PC synthesis and increases brain levels of PC and other
phosphatidylcholines.

Dietary choline or choline secreted into the gut can
be broken down by intestinal bacteria to form trimethyl-
amine and related amine products. This process is
responsible for the fishy odor sometimes detected in
people taking large doses of choline supplements.

Because choline is, by virtue of its quaternary nitro-
gen atom, highly polar, it had generally been assumed that
plasma choline was unavailable to the brain. Further-
more, since brain cells were also thought to be incapable
of synthesizing choline de novo, the ability of cholinergic
nerve terminals to maintain the intracellular choline concentra-
tions needed for ACh synthesis was usually attributed
either to an extraordinarily effective reuptake mechanism
for reutilizing choline formed from the hydrolysis of ACh
or to the uptake into brain of circulating PC or lyso-PC.

Since the poor affinity of choline acetyltransferase, the
enzyme that catalyzes choline’s conversion to ACh, for
choline made it likely that intracellular choline concentra-
tions would control brain ACh synthesis, it was broadly conjectured that choline’s high-affinity uptake
from the synaptic cleft controlled the rate of brain ACh
synthesis.

It is no longer held that brain choline levels are sus-
tained solely by circulating phosphatides or by the high-
affinity uptake of free choline from synapses, or that
variations in high-affinity uptake are responsible for
observed variations in brain choline levels. Choline mol-
eules (but not those of PC or lyso-PC) do readily cross
the BBB and brain cells do indeed synthesize choline
de novo. Physiological variations do occur in choline
levels within brain neurons; however, these result princi-
plally from changes in plasma choline concentrations after
eating choline-rich foods or from choline’s metabolism.

Free choline molecules in brain derive from four
known sources: uptake from the plasma, liberation from
the PC in brain membranes, high-affinity uptake from the
synaptic cleft after ACh released from a cholinergic termi-

nal has been hydrolyzed, and, probably to a minor
tent, the breakdown of newly synthesized PC formed
from the methylation of PE.

The brain can obtain circulating choline via two
routes. Small amounts pass from the blood to the cere-
brospinal fluid through the action of a specific transport
protein, organic cation transporter 2, present in cells
lining the choroid plexus. However, orders of magni-
tude more choline pass bidirectionally between the
blood and the brain’s extracellular fluid by facilitated dif-
fusion. This process is catalyzed by a different transport
protein, localized within endothelial cells that line the
brain’s capillaries. Its action is independent of sodium
and can be blocked by hemicholinium-3.

This transport protein (RBE4) exhibits a relatively
low Km value for choline (estimated variously as
39–42 μM or 20 μM or 220–450 μM). These differences in affinities might reflect the different methods used
for their measurement, but in any case, the protein would
still be unsaturated at physiological plasma choline con-
centrations and its net activity still affected by variations in
these concentrations.

Choline can pass in either direction, based on the
gradient between its blood and brain levels. When
plasma choline levels are elevated (e.g., to 50 μM in the
rat) by consumption of a choline-rich meal, choline tends
to enter the brain, but when plasma choline levels are low,
choline’s flux is in the opposite direction. It has been
estimated the plasma choline concentration in rats
required in order for the net choline flux to be from blood
to brain is about 15 μM; below this concentration, net
choline flux is presumably from brain to blood.
the circulating choline has entered the brain’s extracellular fluid, it can be taken up into all cells by a low-affinity transport protein (Km value, 30–100 μM) or into cholinergic nerve terminals by a high-affinity uptake protein (Km, 0.1–10 μM). The high-affinity process – unlike the passage of choline across the BBB – is energy and sodium dependent.

The choline in membrane PC can be liberated through the actions of the phospholipase enzymes, described above. In brain, the activation of each phospholipase is tightly regulated and, in general, initiated by the interaction of a neurotransmitter or other biologic signal with a receptor coupled to a G protein. For example, the phospholipase C enzymes (which act on PC to yield DAG and phosphocholine, or on PI) and phospholipase D (which acts on PC to yield phosphatidic acid and choline) are all activated when ACh attaches to M1 or M3 muscarinic receptors.

The release of choline from PC can be enhanced, and the reincorporation of choline into PC diminished, by sustained neuronal depolarization. Autocannibalism, occurring when some of the choline is diverted for the synthesis of ACh, may, by decreasing the quantities of phosphatide molecules and thus of neuronal membranes, underlie the particular vulnerability of cholinergic neurons in certain diseases. It can be blocked by providing the brain with supplemental choline.

ACh released into synapses is very rapidly hydrolyzed to free choline and acetate by the acetylcholinesterases (EC 3.1.1.7; AChE) within the cholinergic synapse. Most of the free choline liberated by the hydrolysis of ACh is taken back up into its nerve terminal of origin by a high-affinity choline transporter and either reacetylated to form ACh or phosphorylated for ultimate conversion to membrane PC.

Plasma and brain DHA and EPA

The omega-3 PUFAs DHA (22:6n–3) and EPA (20:5n–3) and the omega-6 PUFAs AA (22:4n–6) are long-chain derivatives of α-linolenic acid (ALA; 18:3n–3) and linoleic acid (LA; 18:2n–6), respectively. ALA and LA are essential dietary constituents for vertebrates, since these animals cannot synthesize them or their polyunsaturated products de novo. Although DHA and EPA as well as AA can be produced in humans through the elongation and desaturation of ALA and LA, respectively, the conversion of ALA to EPA or DHA is slow, since about 75% of available ALA is shunted to β-oxidation. Furthermore, the commercial oils that provide dietary ALA, like safflower, sunflower, and corn oils, also contain very high proportions of LA, thus yielding disproportionately large amounts of AA, which then suppresses the delta-6 desaturase enzyme that would convert LA to AA. Thus, additional EPA and DHA must be obtained from the diet, particularly from high-fat fish or foods fortified with deodorized omega-3 rich oils. No authoritative body has defined a requirement for DHA; intakes as great as 3 g per day or even more have been used to lower plasma triglyceride levels in diabetes mellitus.

The uptakes of circulating PUFAs into the brain and brain cells involve both simple diffusion (also termed “flip-flop”) and protein-mediated transport. DHA, EPA, and AA are then transported from the brain’s extracellular fluid into cells, activated to their corresponding coenzyme A (CoA) species (e.g., docosahexaenoyl-CoA, eicosapentaenoyl-CoA, or arachidonoyl-CoA), and acylated to the sn-2 position of DAG to form PUFA-rich DAG species for incorporation into phosphatides. DHA is acylated by a specific acyl-CoA synthetase, Acsl6, which exhibits a low affinity for this substrate (Km value, 26 μM) relative to usual brain DHA levels (1.3–1.5 μM). Hence, treatments that raise blood DHA levels rapidly increase its uptake into and retention by brain cells.

EPA can be acylated to DAG by the Acyl-CoA synthetase or it can be converted to DHA by brain astrocytes, allowing its effects on brain phosphatides and synaptic proteins, described below, to be mediated by DHA itself. Exogenously administered AA, like DHA, is preferentially incorporated into brain phosphatides as well as into other lipids, e.g., the plasmalogens. AA shares some neurochemical effects with DHA, for example, the ability to activate syntaxin-3, and also has other important functions, e.g., as the precursor of prostaglandins. However, unlike DHA, AA administered orally to laboratory rodents without uridine and choline apparently does not promote synaptic membrane synthesis or dendritic spine formation.

AA is widespread throughout the brain and is particularly abundant in PI and PC, and DHA is concentrated within synaptic regions of gray matter and is especially abundant in PE and PS. In contrast, EPA is found only in trace amounts in brain phosphatides, mostly in PI. No significant differences have been described between the proportions of ingested omega-3 and of omega-6 PUFAs that enter the blood, or between the rates at which radioactively labeled circulating DHA and AA are incorporated into brain phospholipids.

P2Y receptors as mediators of uridine effects

How does exogenous uridine – a precursor for the cytidine compounds utilized in the syntheses of PC and other cellular lipids – increase levels of cellular proteins, specifically of various pre- and post-synaptic neuronal
proteins? Most likely, by a second mechanism in which uridine and its phosphorylated products act as ligands for P2Y receptors that then can activate protein synthesis and normal neuronal differentiation.

Extracellular nucleotides can serve as ligands for a variety of ionotropic P2X and metabotropic P2Y receptors. While P2X receptors recognize adenine nucleotides, P2Y receptors can recognize both adenine and uridine nucleotides. Members of the P2Y family, G-protein-coupled receptors, are widely distributed throughout the body, including within the brain. To date, eight P2Y receptors of human origin (P2Y1, 2, 4, 6, 11, 12, 13, and 14) have been cloned and characterized.

P2Y receptors that recognize adenine but not uridine nucleotides, i.e., the P2Y1, P2Y11, P2Y12, and P2Y13 subtypes, exist principally outside the brain. P2Y2 receptors, in contrast, are abundant in brain and are activated by UTP or ATP; P2Y4 receptors are activated by UTP and P2Y6 receptors by UDP. Their activation, through coupling to phospholipase C, increases intracellular concentrations of DAG, IP3, and calcium.

That uridine nucleotides affect neurite outgrowth as well as neuronal differentiation and function by stimulating P2Y receptors has been demonstrated mainly using in vitro assay systems. UTP increases neurite outgrowth by nerve-growth-factor-stimulated PC-12 cells and the expression of neurofilament proteins and synaptic proteins (e.g., PSD-95); these effects are blocked by P2Y receptor antagonists or by apyrase, a drug that degrades extracellular nucleotides. Such P2Y-receptor-mediated actions could argue for the possible utility of P2Y agonists in treating Alzheimer’s disease, especially since P2Y2 receptors are known to be selectively deficient in the parietal cortex of Alzheimer’s disease brains.

**EFFECTS OF TREATMENT WITH PHOSPHATIDE PRECURSORS ON NEURITE OUTGROWTH AND DENDRITIC SPINE FORMATION**

As discussed above, the formation of a new brain synapse generally follows the interaction of a highly differentiated outgrowth, a dendritic spine, from what will become the postsynaptic neuron, with a terminal bouton of a presynaptic neuron. The number of dendritic spines at steady state in a brain region depends on genetic factors and on the frequency with which the neuron is depolarized or stimulated by synaptic transmission. It is also increased in the hippocampus of animals treated with the uridine-DHA-choline mixture or, less so, with DHA alone. Moreover, uridine, DHA, or choline alone can increase the number of neurites projecting from PC-12 cells. AA, an omega-6 PUFA, fails to increase dendritic spines in vivo but does stimulate neurite outgrowth.

**Uridine and neurite formation by PC-12 cells**

PC-12 cells that had been differentiated by nerve growth factor were exposed to various concentrations of uridine, and the number of neurites that the cells produced was measured. After 4 but not 2 days, uridine significantly and dose-dependently increased the number of neurites per cell. This increase was accompanied by increases in neurite branching and in the levels of the neurite proteins neurofilament M and neurofilament 70. Uridine treatment also increased intracellular levels of CTP and UTP, which suggests it enhanced neurite output both by stimulating PC synthesis and by activating P2Y2 receptors. The increase in neurite output was mimicked by exposing the cells to UTP and could be blocked by various drugs known to antagonize P2Y receptors (e.g., suramin, reactive blue 2, and pyridoxal-phosphate-6-azophenyl-2′,4′ disulfonic acid [PPADS]). Treatment of the cells with uridine or UTP also enhanced the intracellular accumulation of inositol phosphates, and this effect was also blocked by PPADS. Moreover, degradation of nucleotides by apyrase blocked the stimulatory effect of uridine on neuritogenesis.

Uridine is not unique in regulating cell differentiation and metabolism via two separate mechanisms: i.e., as a receptor agonist and as a bulk precursor of CTP needed for phosphatide synthesis. Diacylglycerol also acts in two ways, both as a potent “second messenger” that activates protein kinase C, and as a bulk precursor of CTP needed for phosphatide synthesis, the intracellular levels of which modulate the substrate saturation of CPT. The density of P2Y2 receptors but not other P2 receptors is, as noted above, selectively reduced in brains of patients with Alzheimer’s disease. This could reflect either a loss of postsynaptic structures that contain this protein (e.g., postsynaptic densities) or perhaps the action of a toxin that inhibits neurite outgrowth and ultimately suppresses synapse formation in Alzheimer brains.

As discussed above, mature dendritic spines, the small membranous protrusions extending from postsynaptic dendrites of neurons, form and then represent excitatory glutamatergic synapses. Their numbers in particular brain regions are highly correlated with numbers of synapses, and it has been proposed that more than 90% of excitatory synapses occur on dendritic spines. This suggests that processes that damage the spines (e.g., Aβ, amyloid plaques) or increase spine number (treatment with uridine, DHA, and choline, discussed below) will cause parallel changes in synapse number. The formation of dendritic spines in the hippocampus is induced physiologically by synaptic inputs that induce long-term potentiation in CA1 pyramidal neurons, probably mediated by enhanced calcium influx into the postsynaptic neuron.
The effects of administration of the phosphatide precursors DHA (300 mg/kg) and uridine (as UMP, 0.5%) on dendritic spine number (in CA1 pyramidal hippocampal neurons) were examined in adult gerbils treated daily for 1–4 weeks; animals received one or both compounds, as well as choline. DHA alone caused dose-related increases in spine density, accompanied by parallel increases in membrane phosphatides and in specific pre- and post-synaptic proteins; its effect was doubled if animals also received uridine (UMP). In contrast, administration of the omega-6 PUFA AA, with or without uridine, had no effect on spine density or on phosphatide or synaptic protein levels. DHA administration has been described as promoting cognition, yet its effects on neurotransmission have been obscure. Perhaps its effect on cognition is mediated in part by the increases it produces in numbers of dendritic spines or synapses.

Similar studies were performed on pregnant rats and their offspring. The dams consumed UMP, DHA, or both compounds for 10 days prior to parturition and for 21 days while nursing. By day 21, brains of weanlings exhibited significant increases in membrane phosphatides, in various pre- and post-synaptic proteins (synapsin-1; mGluR1, and PSD 95), and in hippocampal dendritic spine density. Perhaps administering the phosphatide precursors to lactating mothers or to infants could be useful in treating developmental disorders characterized by deficient synapses.

**Physiological and Behavioral Effects of Phosphatide Precursors**

Consumption by rats of a diet containing uridine (as UMP) and choline can increase dopamine (DA) and ACh levels in, and – as assessed using in vivo microdialysis – their release from, corpus striatum neurons. Dietary supplementation of aged male Fischer 344 rats with 2.5% w/w UMP for 6 weeks, ad libitum, increased the release of striatal DA evoked by potassium-induced depolarization ($P < 0.05$). Giving both uridine and DHA amplified uridine’s effect on DA levels. In general, each animal’s DA release correlated with its striatal DA content, measured postmortem. The levels of neurofilament protein 70 and neurofilament M proteins, two markers of neurite outgrowth, were also increased after UMP treatment.

In a similar microdialysis study, ACh release, basally as well as after administration of atropine (a muscarinic antagonist that blocks inhibitory presynaptic cholinergic receptors), was found to be enhanced following UMP consumption (0.5 or 2.5% for 1 or 6 weeks; $P < 0.05$). Thus, giving a uridine source may enhance some cholinergic functions, perhaps by increasing the amount of synaptic membrane or the quantities of ACh stored in synaptic vesicles. Apparently, no data are available on effects of UMP plus DHA on neurotransmitter release.

Indirect evidence that treatment with UMP alone, or with UMP plus DHA, can affect brain neurotransmission also is provided by behavioral studies. Animals received DHA (300 mg/kg) by gavage, UMP (0.5%) in the diet, or both compounds, and hippocampal and striatal forms of memory were measured in rats exposed to environmentally impoverished or enriched environments for 1 month starting at weaning and fed a choline-containing diet. Giving either DHA or UMP improved performance in the hidden version of the Morris water maze (all $P < 0.05$), a hippocampal-dependent task; co-administration of both phosphatide precursors further enhanced performance among environmentally impoverished rats ($P < 0.001$); and neither giving UMP or DHA alone nor giving both compounds affected the performance of rats raised in the enriched environment or the performance by either group on the visible version of the Morris water maze, a striatal-dependent task. Chronic dietary administration of UMP (0.1%) alone for 3 months also ameliorated this impairment among the impoverished rats. In normal adult gerbils, DHA plus choline improved performance on the four-arm radial maze, the T-maze, and the Y-maze tests; co-administering UMP enhanced these increases. These findings demonstrate that a treatment that increases synaptic membrane can enhance cognitive functions in normal animals as well as in those reared in a restricted environment.

**Clinical Applications**

Brains of patients with Alzheimer’s disease are deficient in choline and in DHA and exhibit selective decreases in numbers of P2Y2 receptors and dendritic spines and synapses. Since the loss of dendritic spines or synapses precedes neuronal degeneration and is associated with cognitive deficits in both patients and animal models of Alzheimer’s disease, it can be hypothesized that impaired synaptic signaling is an initial process in developing the pathologic findings and behavioral characteristics of Alzheimer’s disease. The loss of spines may result from toxic effects of Aβ, particularly that in senile plaques.

Since administering a uridine-DHA-choline mixture improved cognition and increased dendritic spine number synaptic membrane levels, it seemed reasonable to explore whether this treatment might also improve cognition in impaired patients with Alzheimer’s disease. A randomized, controlled, double-blind, parallel-group, multicenter, multi-country clinical trial involving 212 drug-naive subjects with mild Alzheimer’s disease and directed by P Scheltens was thus performed to examine the effects of a mixture including DHA, UMP, choline,
Souvenaid*, and other nutrients (e.g., vitamins B₆, B₁₂, and folic acid) on a delayed verbal memory task (derived from the Wechsler Memory Scale – revised) and the item-modified Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog) at 12 weeks. The trial was preregistered with the Dutch Trial Registry (no. ISRCTN 722254645).

In the group receiving the mixture, a significant benefit was found in mild and very mild Alzheimer’s disease on the verbal memory task. The unadjusted analyses showed no significant effect on the modified ADAS-cog test. However, the baseline modified ADAS-cog score was a predictor for the intervention effect, i.e., patients with a higher baseline score showed a greater effect after treatment with the mixture. Intervention with the mixture was well tolerated (compliance was 94%) and safe. This proof-of-concept study was interpreted as demonstrating that giving a drink that contains DHA, uridine, choline, and other nutrients for 12 weeks can improve memory in mild and very mild Alzheimer’s disease, and that further studies now in progress are justified.

CONCLUSION

The rates at which brain neurons form new dendritic spines and then synapses depend upon brain levels of three limiting compounds – uridine, DHA, and choline – that are precursors of the phosphatides in neuronal membranes. Hence, oral administration of these compounds can increase brain phosphatide levels. Moreover the uridine, acting as an agonist for P2Y2 receptors (and perhaps the DHA, via other receptors), concurrently stimulates the production of pre- and post-synaptic proteins and activates the mechanisms that cause synaptic membrane to be shaped into neurites, dendritic spines, and, ultimately, synapses. Administration of the three precursors for several weeks can enhance cognitive functions and neurotransmitter release in experimental animals. Moreover, their administration to patients with mild Alzheimer’s disease, along with the B vitamins that promote hepatic choline synthesis, significantly improved memory in a clinical trial involving about 220 subjects. Three additional trials are underway.

Acknowledgments

The authors acknowledge with thanks the invaluable editorial assistance of Betty Griffin.

Studies in the authors’ laboratories described in this report were supported by the National Institutes of Health and the Center for Brain Sciences and Metabolism Charitable Trust, Cambridge, Massachusetts, USA.

Declaration of interest. RJ Wurtman is a consultant for Danone Nutricia. The other authors have no relevant interests to declare.

REFERENCES


47. Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine 5’-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res. 2007;1182:50–59.


Dear Author,

During the preparation of your manuscript for publication, the questions listed below have arisen. Please attend to these matters and return this form with your proof.

Many thanks for your assistance.

<table>
<thead>
<tr>
<th>Query References</th>
<th>Query</th>
<th>Remark</th>
</tr>
</thead>
<tbody>
<tr>
<td>q1</td>
<td>AUTHOR: The title has been rephrased to make it shorter. Please confirm the accuracy of the shortened title.</td>
<td></td>
</tr>
<tr>
<td>q2</td>
<td>AUTHOR: Please spell out the first name of each author.</td>
<td></td>
</tr>
<tr>
<td>q3</td>
<td>AUTHOR: Since “latter” refers to the last of two, “latter” was changed to “postsynaptic dendritic spines. If you would prefer alternative phrasing, please modify.</td>
<td></td>
</tr>
<tr>
<td>q4</td>
<td>AUTHOR: The reference citations have been renumbered from Reference 35 (originally Reference 36) onward, and the reference list has been renumbered accordingly. Please check all of the references carefully and confirm their accuracy.</td>
<td></td>
</tr>
<tr>
<td>q5</td>
<td>AUTHOR: Is the revised sentence correct?</td>
<td></td>
</tr>
<tr>
<td>q6</td>
<td>AUTHOR: Please check these website addresses and confirm that they are correct. (Please note: it is the responsibility of the author(s) to ensure that all URLs given in this article are correct and useable.)</td>
<td></td>
</tr>
<tr>
<td>q7</td>
<td>AUTHOR: Is the revised sentence correct?</td>
<td></td>
</tr>
<tr>
<td>q8</td>
<td>AUTHOR: Correct to change mmoles to mmol?</td>
<td></td>
</tr>
<tr>
<td>q9</td>
<td>AUTHOR: Are the parentheses in this sentence placed correctly?</td>
<td></td>
</tr>
<tr>
<td>q10</td>
<td>AUTHOR: Is the revised sentence correct?</td>
<td></td>
</tr>
<tr>
<td>q11</td>
<td>AUTHOR: Is “coenzyme A” correct for CoA?</td>
<td></td>
</tr>
<tr>
<td>q12</td>
<td>AUTHOR: Correct to change “and” to “or”?</td>
<td></td>
</tr>
<tr>
<td>q13</td>
<td>AUTHOR: Is the revised sentence correct?</td>
<td></td>
</tr>
<tr>
<td>q14</td>
<td>AUTHOR: Could “amyloid” be deleted here?</td>
<td></td>
</tr>
<tr>
<td>q15</td>
<td>AUTHOR: Correct to change 2,5% to 2.5% here?</td>
<td></td>
</tr>
<tr>
<td>q16</td>
<td>AUTHOR: City and state for the Trust have been added. Are they correct?</td>
<td></td>
</tr>
<tr>
<td>q17</td>
<td>AUTHOR: Is it correct that the coauthors on this manuscript have no interests to declare? Please confirm.</td>
<td></td>
</tr>
<tr>
<td>q18</td>
<td>AUTHOR: Please note that reference 4 is the same as 35, reference 1 is the same as 51, so the latter were deleted and the remaining references renumbered; please confirm this is correct.</td>
<td></td>
</tr>
<tr>
<td>q19</td>
<td>AUTHOR: There does not seem to be an 8th edition of this book. Did you mean 3rd edition? If 8 was a chapter number, it is not needed.</td>
<td></td>
</tr>
<tr>
<td>q20</td>
<td>AUTHOR: If this reference has now been published online, please add relevant DOI information. If this reference has now been published in print, please add relevant page information. If it has not been published, the citation should be removed from the reference list and cited in the text as “unpublished data”. The remaining references will need to be renumbered accordingly.</td>
<td></td>
</tr>
<tr>
<td>q21</td>
<td>AUTHOR: Reference 126 in the original file (now ref. 124) has not been cited in the text. Please indicate where it should be cited; or delete from the reference list and renumber the references in the text and reference list.</td>
<td></td>
</tr>
</tbody>
</table>